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Abstract
Deletion mutations ofWAS are relatively rare and the precise localization of large deletions in the genome has
rarely been described in previous studies. We report here a 5-month-old boy with a large deletion mutation
in WAS that completely abolished protein expression. To localize the deletion, a 2816-bp-length sequence
that spans between exons 9 and 12 was amplified. PCR amplification of the patient’s sample revealed a
single band of about 1 kb in contrast to the 2816-bp-amplicon in the control. Genomic DNA sequencing of the
patient revealed a 1595-bp-deletion and an adenine insertion (g.5247_6841del1595insA). This large deletion of
WAS resulted in partial loss of exon 10 and intron 11, and a complete loss of intron 10 and exon 11.
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The Wiskott–Aldrich syndrome (WAS; OMIM301000) is a
rare, X-linked primary immunodeﬁciency disorder inherited in
an autosomal recessive manner, and it is caused by mutation
of the WAS protein gene (WAS) resulting in defective expres-
sion and function of WASP (1–4). Clinical and hematologic
characteristics of WAS include early-onset gastrointestinal
bleeding, recurrent infections, eczema, micro-thrombocytope-
nia, and platelet dysfunction (1, 2, 5). WAS has 12 exons and
encodes a 502 amino acid hematopoietic cell lineage-speciﬁc
protein (6–10).
Reports on genotype–phenotype correlation in WAS patients
are contradicting which may have been related to the lack of
carefully collected clinical data over time. We report here a
WAS patient with an InDel mutation and review the previ-
ously published literature of gene gross deletions.
Patients and methods
The male patient studied in detail in this work was born from
the second, uneventful pregnancy of his mother. The parents
are clinically healthy. The mother’s ﬁrst pregnancy ended in
spontaneous abortion at 5 wk of gestation. From 3 wk of age,
he presented with bloody diarrhea, and erythematous maculo-
papular rash appearing on his face. By the age of 5 wk, the
rash spread to the cervical region and the superior part of his
trunk, and he continued to have recurrent bloody stools. At
6 wk of age, physical examination revealed pallor, eczema,
mucosal petechiae, and oral candidiasis. Laboratory examina-
tion showed anemia (hemoglobin, 6.5 g/dL), thrombocytope-
nia (platelets, 35 9 103/lL), and elevated C-reactive protein
level (260 mg/L). At the age of 7 wk, he was still thrombocy-
topenic (platelets, 21–85 9 103/lL), and the mean platelet
volume (MPV) was between 7.5 and 9.9 fL. Serum immuno-
globulin levels were: IgA, 0.6 g/L; IgG, 3.95 g/L; IgM,
0.34 g/L. Bone marrow examination showed abundant throm-
bocytopoiesis and thrombocytic anisocytosis. At the age of
3½ months, the MPV decreased to 6.5–6.9 FL, and the patient
continued to have recurrent bloody diarrhea. Despite several
platelet transfusions, he presented with persistent micro-
thrombocytopenia (platelets, 12 9 103/lL; MPV<7 FL) at age
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of 5 month. The serum immunoglobulin G level gradually
decreased and the patient was treated with 400 mg/kg
IVIG on two subsequent days. Blood lymphocyte subset
analysis revealed decreased CD8+ T cell count (0.07–
0.12 9 10³/lL), B cell count (0.11 9 10³/lL), and NK
cell number (0.17 9 10³/lL). The number of CD19+ lym-
phocytes decreased from 1.16 9 10³/lL to 0.56 9 10³/lL
at 11 months of age; CD4+ T cell count decreased from
1.34 9 10³/lL to 0.69 9 10³/lL, CD8 + T cell number
lowered from 0.12 9 10³/lL to 0.05 9 10³/lL; CD4/CD8
ratio was constantly elevated; the NK number was vari-
able, normal, or low. After informed consent was obtained
from the parents, blood samples were collected from the
patient, the mother, and healthy controls. All the studies
described here were approved by the Regional Ethics
Committee of the University of Debrecen and by the insti-
tutional review boards of the centers at which the patients
were managed.
Genomic DNA analysis
Genomic DNA (gDNA) was extracted from blood leuko-
cytes and immortalized B cells according to standard pro-
tocols. gDNA sequences were analyzed by amplifying
exons 1–12 and the ﬂanking intronic regions of WAS by
PCR. Sequence variations were described with respect to
a reference sequence, NCBI NG_007877.1 for WAS. To
identify the location of deletion, a 2816-bp-length
sequence was ampliﬁed that included exons 9 and 12
using AccuTaq LA DNA Polymerase (Sigma-Aldrich Ltd.,
Germany5 ) with the primers 9–12 F (CGACGCCGAGA
CCTCTAAACTTATC) and 9–12 R (CAGCAAGTAACTC
AGCCACTCAGTC).
Flow cytometry
Whole blood cells were blocked with Human IgG Blocking
solution (Sigma-Aldrich, St. Louis, MO, USA). The cells
were stained with phycoerythrin (PE)-conjugated CD3 anti-
body (BD, San Jose, CA, USA) and ﬁxed with Fix Medium
A (Invitrogen Corp., Carlsbad, CA, USA), washed with
phosphate buffered saline containing 0.5% bovine serum
albumin and 2% fetal bovine serum (PBS/BSA/FBS). Cells
were permeabilized with Perm Medium B (Invitrogen) and
were or were not (negative control) stained with anti-human-
WASP rabbit monoclonal antibody (Abcam, Cambridge,
MA, USA) and isotype-matched control rabbit IgG mAb
(Sigma-Aldrich). After 30 min incubation, cells were washed
with PBS/BSA/FBS and labeled by Alexa Fluor 488 conju-
gated anti-rabbit-IgG (Cell Signaling, Eugene, OR, USA) as
secondary antibody for 30 min in Perm Medium B. Samples
were washed twice with PBS/BSA/FBS, ﬁxed in 1% para-
formaldehyde containing PBS and immediately analyzed
with an AccuriC6 cytometer.
Western blotting
Peripheral blood mononuclear cells (PBMCs; 3 9 106) were
treated with lysis buffer and protease inhibitor cocktail
(Sigma-Aldrich). Samples were mixed with equal volumes
of Laemmli loading buffer (Sigma-Aldrich) and incubated at
100°C for 10 min. Total protein (10 lg) was electrophoresed
on 10% sodium dodecilsulfate-polyacrylamide gel and electro
blotted into a polyvinylidene ﬂuoride membrane. Next,
anti-human-WASP rabbit monoclonal antibody (Abcam,
Cambridge, MA, USA), and for actin detection anti-Actin
rabbit monoclonal antibody (Sigma-Aldrich) were added
and incubated overnight at 4°C. Next day, membranes were
incubated with Horseradish peroxidase (HRP)-labeled afﬁn-
ity-puriﬁed goat anti-rabbit IgG (Sigma-Aldrich) as secondary
antibody. WASP and actin bands were visualized by incuba-
tion with SuperSignal West Femto Maximum Sensitivity
Substrate (Thermo Scientiﬁc, Rockford, IL, USA).
Results
Genetic findings
PCR ampliﬁcation of the 12 exons of WAS was performed
by using gDNA. Agarose gel electrophoresis of exons 1–9
and 12 revealed appropriate length bands and normal
sequences of nucleotides was found by sequencing (Fig. 1) 6.
In case of exon 10 and 11, the amplicons were undetectable.
To determine the boundaries of the WAS deletion gDNA
between exons 9 and 12 was ampliﬁed. In a normal control,
we detected a 2816-bp-length amplicon whereas the patient
5000 bp 
3000 bp 
1000 bp 
500 bp 
P M C MW
2816 bp
1221 bp
Figure 1 Agarose gel electrophoresis showing deletion of WAS in the
patient (P) and his mother (M). Agarose gel electrophoresis of a 2816-
bp-sequence of WAS from exon 9 (forward primer) to exon 12
(reverse primer) was performed in a healthy control individual (C). In
the patient’s sample, a single band of about 1 kb was detected (P). In
the mother’s sample, agarose gel electrophoresis showed two ampli-
cons indicating that she was carrier for the deletion mutation (M).
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a smaller, about 1000-bp-length amplicon was found. gDNA
sequencing revealed a 1595-bp-deletion of WAS and a single
adenine insertion in the patient (g.5247-6841del1595insA;
Fig. 2A). In the mother, two bands were identiﬁed, one rep-
resenting the normal and one representing the mutant alleles
(Fig. 2A). The InDel mutation affected exons 10–11 and
caused a frame shift (R439 fs) (Fig. 2B).
WASP expression in white blood cells
WASP expression in blood cells of the patient, his mother,
and healthy controls was studied by ﬂow cytometry after intra-
cellular staining. WASP expression (red line) was compared
to that of isotype control (blue line). Cells isolated from the
mother and healthy controls expressed WASP, whereas negli-
gible amount of WASP was detected in PBMC of the patient
(Fig. 3A). Western blot analysis showed that PBMC derived
from the mother contained full length WASP (66 kDa) simi-
larly to that of travel and healthy control cells (Fig. 3B). In
contrast, WASP was not detectable in PBMC of the patient.
Discussion
The Wiskott–Aldrich syndrome may result from missense
and nonsense mutations, small or large deletions, insertions,
and splice anomalies of the WAS gene. In some of the cases
described before, the mutation leads to complete loss of the
WASP, while in others a truncated or mutated protein is
expressed (WASP positive patients). Deletions in WAS were
in most cases identiﬁed as short (1–12 bp) whereas the
occurrence of large deletions have been rare (11–22)
(Fig. 4). These genetic aberrations can span from a single
exon to larger regions involving two or more exons with the
encompassed introns or, in certain cases, the entire gene can
be deleted (15). Here, we review the literature describing
large deletions together with their genomic and clinical fea-
tures and extend the list with a newly identiﬁed deletion
mutation.
We report here the identiﬁcation of a mutation affecting
WAS in a Romanian patient based on laboratory and clinical
ﬁndings. His mutation proved to be a novel InDel localized
Patient Mother
Control
C   A   A   A  T  C                                                             G  C G A  T CC G G C A G G C A G T G G C
C    A   A   A  T C A   G  C G   A   T  C
del1595bp and insA 
C    A   A   A  T C A   G  C G   A   T  C
del1595bp and insA 
C    A G    T G  G   C   G  C G   A   T  C
1595 bp
g.5247_6841del1595insA
R439fs
PR VD WH2 CD     PH WH1 GBD
1 502
               
PR     PH WH1 GBD     
1
A
B
Figure 28 (A) Mutation analysis of the InDel
mutation of WAS. Electropherogram of
genomic DNA sequencing of the patient shows
a 1595-bp-deletion and a single adenine
insertion (shown in brackets) at the site of the
deletion. Electropherogram of the mother
shows heterozygosity for the InDel mutation.
(B) Schematic representation of InDel mutation
on the WAS gene and protein in the patient.
The 1595-bp-deletion located in exon, intron 10
and exon, intron 11. The mutation caused a
frame shift, and the order of amino acid was
damaged from the position 439. PH, pleckstrin
homology; WH, WAS homology; GBD, GTP-ase
binding; PR, proline rich; VD, verprolin
homology; and CD, cofilin homology domain.
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to the 30 end of the WAS gene. Genetic analysis revealed
that a breakpoint occured in exon 10 at nucleotide position
5246 of WAS and resulted in a 1595-bp-deletion with a sin-
gle adenine insertion at the site of the deletion. The aberra-
tion causes the loss of part of exon 10, lack of the entire
intron 10 and exon 11 and partial loss of intron 11. Flow
cytometry and Western blot analysis showed no WASP
expression in peripheral lymphocytes of the patient. The
antibody we used recognizes the C-terminus of the human
WAS protein (exon 12), and the identiﬁed mutation is
located upstream from the epitope. Therefore, our data sug-
gest that due to the mutation, the normal size and functional
protein was not presented in the patient’s cells.
In a Taiwanese patient, the regulatory region of WAS gene
was also affected, the proximal promoter and the ﬁrst two
exons of the gene were found to be deleted (11, 12). As a
result of this unique mutation, WASP was not detectable in
the patient’s lymphocytes and caused impaired mitogen anti-
gen induced cell proliferation and NK cell activity. Low
level of CD4+ memory cells and defected lymphocyte prolif-
eration increased the susceptibility of the patient to infec-
tions and led to the development of a severe WAS
phenotype (11). In another Taiwanese patient, the ﬁrst 4
exons could not be ampliﬁed from genomic DNA derived
from peripheral lymphocytes and WASP expression was
undetectable. Lack of WASP expression also resulted in a
severe form of classical WAS (13). In a Caucasian patient, a
15 800-bp-long Alu-mediated deletion was described, com-
prising exons 1–6, a part of intron 6 and 13 kb of the
upstream region, including the proximal and distal WAS
gene promoters. WAS protein in PBMCs of the patient
could not be detected and a severe phenotype of WAS was
observed (14).
A large deletion encompassing exons 1–7 was identiﬁed
which led to lack of WASP expression in mononuclear cells
or EBV-transformed B cell lines derived from a patient and
resulted in severe WAS phenotype (15). In another patient,
an approximately 2-kb-long deletion was described, involv-
ing exons 3–7 and seemed to have been created by the
fusion of introns 2 and 7. WASP could not be detected in
cell extracts from this patient, and he had a classical severe
WAS phenotype with autoimmunity (16, 17). A 322-bp-long
deletion was detected in a Russian patient who spanned
introns 3–4 and exons 4–5 (18). A single exon deletion
(exon 7) was reported in a Japanese patient who caused lack
of WASP expression and severe phenotype accompanied by
malignancy (16). In one Argentinian patient, deletion started
also from exon 7 and was found to extend to intron 11 (19),
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Figure 3 9Detection of WASP expression in patient, his mother, and healthy controls. (A) Analysis of intracellular Wiskott–Aldrich syndrome pro-
tein (WASP) expression by flow cytometry. WASP expression (red line), isotype control (blue line), and negative control (black line) data are
shown. Expression of WASP was in cells from the mother and healthy controls was comparable, and negligible WASP expression was detected
in the patient’s sample. (B) Analysis of WASP expression by Western blot. Normal WASP expression was identified from cell lysates in the
patient’s mother and healthy controls in contrast that no protein expression in patient’s sample.
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while in another patient the deletion covered the 30 terminal
region of WAS gene from intron 8 to 30 UTR (20).
There have been two different large deletions reported
affecting the 30 end of the WAS gene. In the ﬁrst case dele-
tion spans, the last two exons of the WAS gene with the
proximal breakpoint located within intron 10. This caused
the development of classical WAS phenotype (21). The sec-
ond happened to be a complex mutation as the deleted
4.3 kb fragment covered intron 11, coding exon 12 and 30
UTR of the WAS gene, as well as DNA sequences upstream
of the promoter region of the subsequent SUV39H1 gene.
Additionally, upstream from the large deletion, a small 9-
bp-deletion and the inversion of a 151-bp-long region,
involving an adenine insertion at position 148 of the inverted
sequence, were also identiﬁed. The polyA signal of wild type
WAS, located in exon 12, was absent in the patient’s sample
as a consequence of the mutation. Stable truncated but non-
functional protein expression was also detected inducing
classical WAS phenotype (22). In another two intriguing
cases, the deletions affected large part of the WAS gene. In
the ﬁrst patient, only exon 12 could be ampliﬁed from geno-
mic DNA, while in the second patient the entire WAS gene
was documented to be missing (16, 23). Consequently,
WASP expression could not be detected in either patient.
Among all the mutations that have been identiﬁed in
WAS, large deletions constitute an extremely small fraction.
Based on this limited number of known cases, no preferen-
tially affected gene regions can be identiﬁed. All of the large
deletions led to either the total loss of WASP or to the
expression of a nonfunctional truncated variant. These were
manifested without exception in severe classical WAS phe-
notype. Therefore, early detection of large deletion mutation
is crucial to initiate therapies including stem cell transplanta-
tion or gene therapy.
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